Blinatumomab — A New Standard of Care in Acute Lymphoblastic Leukemia
Mené sur 709 patients pédiatriques atteints d'une leucémie lymphoblastique aiguë à cellules B et à haut risque (durée médiane de suivi : 2,9 ans), cet essai randomisé évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité du blinatumomab en remplacement d'une chimiothérapie
Research involving the treatment of pediatric acute lymphoblastic leukemia (ALL) established the paradigm for improving survival in cancer. In iterative clinical trials conducted by cooperative groups, long-term survival has improved from less than 10% to 90% owing to the use of improved multidrug regimens and treatment tailored to clinical and biologic characteristics.1 However, subgroups of patients have persistently inferior outcomes. The AIEOP-BFM (Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin–Frankfurt–Münster) ALL 2017 Consortium used leukemic cytogenetic and molecular characteristics and chemotherapy responses to define a subgroup of patients with ALL who have the highest risk of relapse; disease in . . .
New England Journal of Medicine , éditorial, 2026